Elevai Biosciences has engaged KCRN Research to support the Company’s initial efforts to prepare for an Investigational New Drug application to the FDA for EL-22 in the treatment of obesity and muscle ...
EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines The Investigational New Drug application is planned for submission to the U.S. Food ...
Inhibiting a growth factor that keeps muscles from getting too big may optimize recovery of injured soldiers, researchers say. Bone biologists are studying two myostatin inhibitors in mice with limb ...
Researchers at Nationwide Children’s Hospital have shown that a gene delivery strategy that produces follistatin — a naturally occurring protein that inhibits myostatin, a growth factor expressed ...
To obtain a myostatin propeptide that would have a more potent inhibitory effect on myostatin, we mutated the propeptide at the BMP-1/TLD cleavage site by replacing the aspartate at position 76 by an ...
“Myostatin is currently being pursued as a leading approach for muscle preservation in clinical trials with GLP-1 medications,” said Deniel Mero, Co-founder of Elevai Biosciences. “We are excited by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback